MA40098A1 - Identification of a patient's response to administration of a s1p receptor modulator. - Google Patents

Identification of a patient's response to administration of a s1p receptor modulator.

Info

Publication number
MA40098A1
MA40098A1 MA40098A MA40098A MA40098A1 MA 40098 A1 MA40098 A1 MA 40098A1 MA 40098 A MA40098 A MA 40098A MA 40098 A MA40098 A MA 40098A MA 40098 A1 MA40098 A1 MA 40098A1
Authority
MA
Morocco
Prior art keywords
patient
ethyl
benzyloxyimino
azetidine
trifluoromethyl
Prior art date
Application number
MA40098A
Other languages
French (fr)
Inventor
Hubert Borell
Anne Gardin
Yi Jin
Eric Legangneux
Mike Ufer
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA40098A1 publication Critical patent/MA40098A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un procédé d'évaluation de la dose thérapeutique appropriée d'acide 1-{4-[1-(4-cyclohexyl-3-trifluorométhyl-benzyloxyimino)-éthyl]-2-éthyl-benzyl}-azétidine-3-carboxylique à administrer à un patient qui en a besoin, comprenant les étapes consistant à : (i) tester si le patient possède ou non le mauvais génotype métaboliseur; et (ii) si le patient ne possède pas le mauvais génotype métaboliseur, administrer l'acide 1-{4-[1-(4-cyclohexyl-3-trifluorométhyl-benzyloxyimino)-éthyl]-2-éthyl-benzyl}-azétidine-3-carboxylique, ou un sel de celui-ci acceptable sur le plan pharmaceutique, au patient à la dose thérapeutique habituelle; et (iii) si le patient possède le mauvais génotype métaboliseur, ou (a) administrer l'acide 1-{4-[1-(4-cyclohexyl-3-trifluorométhyl-benzyloxyimino)-éthyl]-2-éthyl-benzyl}-azétidine-3-carboxylique, ou un sel de celui-ci acceptable sur le plan pharmaceutique, au patient à une dose thérapeutique inférieure à celle de la dose thérapeutique habituelle; ou (b) ne pas administrer l'acide 1-{4-[1-(4-cyclohexyl-3-trifluorométhyl-benzyloxyimino)-éthyl]-2-éthyl-benzyl}-azétidine-3-carboxylique, ou un sel de celui-ci acceptable sur le plan pharmaceutique, au patient.The invention relates to a method for evaluating the appropriate therapeutic dose of 1- {4- [1- (4-cyclohexyl-3-trifluoromethyl-benzyloxyimino) -ethyl] -2-ethyl-benzyl} -azetidine-3 -carboxylic agent to be administered to a patient in need thereof, comprising the steps of: (i) testing whether or not the patient has the wrong metabolizing genotype; and (ii) if the patient does not have the wrong metabolizing genotype, administer 1- {4- [1- (4-cyclohexyl-3-trifluoromethyl-benzyloxyimino) -ethyl] -2-ethyl-benzyl} -azetidine -3-carboxylic acid, or a pharmaceutically acceptable salt thereof, to the patient at the usual therapeutic dose; and (iii) if the patient has the wrong metabolizing genotype, or (a) administering 1- {4- [1- (4-cyclohexyl-3-trifluoromethyl-benzyloxyimino) -ethyl] -2-ethyl-benzyl} azetidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof, to the patient at a therapeutic dose lower than that of the usual therapeutic dose; or (b) do not administer 1- {4- [1- (4-cyclohexyl-3-trifluoromethyl-benzyloxyimino) -ethyl] -2-ethyl-benzyl} -azetidine-3-carboxylic acid, or a salt of it is pharmaceutically acceptable to the patient.

MA40098A 2013-04-04 2017-03-08 Identification of a patient's response to administration of a s1p receptor modulator. MA40098A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361808406P 2013-04-04 2013-04-04

Publications (1)

Publication Number Publication Date
MA40098A1 true MA40098A1 (en) 2018-06-29

Family

ID=58501222

Family Applications (2)

Application Number Title Priority Date Filing Date
MA38453A MA38453B1 (en) 2013-04-04 2013-04-19 Identification of a patient's response to an administration of a s1p receptor modulator
MA40098A MA40098A1 (en) 2013-04-04 2017-03-08 Identification of a patient's response to administration of a s1p receptor modulator.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA38453A MA38453B1 (en) 2013-04-04 2013-04-19 Identification of a patient's response to an administration of a s1p receptor modulator

Country Status (1)

Country Link
MA (2) MA38453B1 (en)

Also Published As

Publication number Publication date
MA38453A1 (en) 2016-10-31
MA38453B1 (en) 2017-07-31

Similar Documents

Publication Publication Date Title
Janicak et al. Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depression: assessment of relapse during a 6-month, multisite, open-label study
Coluzzi et al. Non-analgesic effects of opioids: opioid-induced nausea and vomiting: mechanisms and strategies for their limitation
Ehieli et al. Analgesia in the surgical intensive care unit
PH12015502291A1 (en) Identifying patient response to s1p receptor modulator administration
BR112014007357A2 (en) therapeutic monitoring methods of nitrogen scanning drugs
Gommoll et al. A randomized, double-blind, placebo-controlled study of flexible doses of levomilnacipran ER (40–120 mg/day) in patients with major depressive disorder
MX2021000794A (en) Methods of using a gip/glp1 co-agonist for therapy.
Demirel et al. Comparison of patient‐controlled analgesia versus continuous infusion of tramadol in post‐cesarean section pain management
Chang et al. Efficacy and safety of olorinab, a full agonist of the cannabinoid receptor 2, for the treatment of abdominal pain in patients with irritable bowel syndrome: results from a phase 2b randomized placebo‐controlled trial (CAPTIVATE)
Lee et al. Hyperprolactinemia induced by low‐dosage amisulpride in Korean psychiatric patients
MA40098A1 (en) Identification of a patient's response to administration of a s1p receptor modulator.
Gibbs et al. An audit of the statistical validity of conclusions of clinical superiority in anaesthesia journals
Riccó et al. Cardiovascular effects of orotracheal intubation following anesthetic induction with propofol, ketamine-propofol, or ketamine-diazepam in premedicated dogs
Schug et al. Cardiovascular safety of the cyclooxygenase-2 selective inhibitor parecoxib sodium: Review of pooled data from surgical studies: A-849
Askari et al. Carvedilol therapy in pediatric patients with dilated cardiomyopathy
Collister et al. Overexpression of copper/zinc superoxide dismutase in the median preoptic nucleus improves cardiac function after myocardial infarction in the rat
Schmidt et al. P249 Effect Size Of Open-label Versus Double-blind Administration Of Tiotropium In Trials Investigating Health-related Quality Of Life In Copd
Umbricht et al. A double-blind placebocontrolled study of the antidepressant effects of the mGlu2 negative allosteric modulator RG1578 in patients with inadequate response to antidepressant therapy
Grotsch Flupentixol/olanzapine/sulpiride/thioridazine
Cappellini Diaphragmatic function in Anesthesia and Intensive Care Unit: Role of ultrasonography in assessing postoperative residual curarization
Mangoni Check for The Impact of Ageing on Pharmacokinetics Arduino A. Mangoni and Elzbieta A. Jarmuzewska
Pathak et al. Comparative study on xylazine, bupivacaine and buprenorphine with ketamine as lumbosacral spinal analgesia in uremic buffalo calves
Werremeyer Retrospective review of a case of serotonin syndrome after discontinuation of risperidone: Was withdrawal neuroleptic malignant syndrome missed?
Singh et al. Effect of ondansetron on sensory level produced by intrathecal bupivacaine
MA38310A1 (en) Combination drug comprising phenylephrine and paracetamol